CV SCIENCES, INC. (OTCMKTS:CVSI) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure

On September 12, 2017, CV Sciences, Inc. (the “Company”) hosted a shareholder update conference call and provided shareholders highlights of the Company’s latest updates and accomplishments during 2017 and strategic initiatives moving forward. The Company published materials in connection with the presentation, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference solely for purposes of this Item 7.01 disclosure.

The information set forth under this Item 7.01 of this Current Report on Form 8-K (“Current Report”), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in this Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 9.01Financial Statements and Exhibits.

(d)Exhibit

99.1CV Sciences, Inc. Corporate Update, dated September 12, 2017.

CV Sciences, Inc. Exhibit
EX-99.1 2 cvsciences_8k-ex9901.htm POWERPOINT PRESENTATION Exhibit 99.1   CBD – BASED PHARMACEUTICAL & CONSUMER PRODUCTS Corporate Update September 12,…
To view the full exhibit click here

About CV SCIENCES, INC. (OTCMKTS:CVSI)

CV Sciences, Inc. is a life science company. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.